Duncan Moore

Duncan Moore has a long history of work experience in various industries. In 2021, they became a Non Executive Director for ASP Isotopes Inc and GH Research. In 2020, they were appointed Chairman of Allarity Therapeutics. In 2015, they became Deputy Chairman of Braidlock. In 2013, they were appointed Chairman of Lamellar Biomedical. In 2016, they became a Non Executive Director for Forward Pharma A/S. In 2007, they became a Partner at East West Capital Partners. Finally, in 1991, they began their career as a Managing Director at Morgan Stanley.

Duncan Moore received their PhD in Biochemistry from the University of Cambridge between 1980 and 1985. Prior to this, they obtained a BSc in Biochemistry Microbiology from the University of Leeds between 1977 and 1979. Duncan's educational journey began at Merchsiton Castle School from 1972 to 1977.